Animal models in HIV-1 protection and therapy

Current Opinion in HIV and AIDS

Volumn 10, Issue 3, 2015, Pages 170-176

  Hessell, Ann J ^a   Haigwood, Nancy L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

HIV 1; humanized mice; Keywords animal models; nonhuman primate; simian immunodeficiency virus (SIV); simian human immunodeficiency virus (SHIV)

Indexed keywords

MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANIMAL TESTING REFINEMENT; B LYMPHOCYTE; DISEASE TRANSMISSION; DRUG EFFICACY; EFFECTOR CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOREGULATION; INFECTION PREVENTION; NONHUMAN; PRIMATE; PRIORITY JOURNAL; REVIEW; RHESUS MONKEY; T LYMPHOCYTE; VIREMIA; VIRUS PATHOGENESIS; VIRUS TRANSMISSION; ANIMAL; DISEASE MODEL; HIV INFECTIONS; IMMUNOLOGY; MACACA; MOUSE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTI-HIV AGENTS; DISEASE MODELS, ANIMAL; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MACACA; MICE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84928574709     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000152     Document Type: Review

References (54)

1. Chahroudi A, Cartwright E, Lee ST, et al. Target cell availability, rather than breast milk factors, dictates mother-to-infant transmission of SIV in sooty mangabeys and rhesus macaques. PLoS Pathogens 2014; 10:e1003958.
2. Chahroudi A, Bosinger SE, Vanderford TH, et al. Natural SIV hosts: showing AIDS the door. Science 2012; 335:1188-1193.
3. SalgadoM, Swanson MD, Pohlmeyer CW, et al. HLA-B-57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4 T cell depletion in humanized BLT mice. J Virol 2014; 88:3340-3352.
4. Sandler NG, Bosinger SE, Estes JD, et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 2014; 511:601-605.
5. Cartwright EK, McGary CS, Cervasi B, et al. Divergent CD4 T memory stem cell dynamics in pathogenic and nonpathogenic simian immunodeficiency virus infections. J Immunol 2014; 192:4666-4673.
6. Hong JJ, Amancha PK, Rogers KA, et al. Early lymphoid responses and germinal center formation correlate with lower viral load set points and better prognosis of simian immunodeficiency virus infection. J Immunol 2014; 193:797-806.
7. Roederer M, Keele BF, Schmidt SD, et al. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature 2014; 505:502-508.
8. Henning TR, Hanson D, Vishwanathan SA, et al. Short communication: viremic control is independent of repeated low-dose SHIVSF162p3 exposures. AIDS Res Hum Retroviruses 2014; 30:1125-1129.
9. Bernard-Stoecklin S, Gommet C, CavarelliM, LeGrand R. Nonhuman primate models for cell-associated simian immunodeficiency virus transmission: The need to better understand the complexity of HIV mucosal transmission. J Infect Dis 2014; 210 (Suppl 3):S660-S666.
10. Carias AM, McCoombe S, McRaven M, et al. Defining the interaction of HIV-1 with the mucosal barriers of the female reproductive tract. J Virol 2013; 87:11388-11400.
11. Del Prete GQ, Ailers B, Moldt B, et al. Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins. Cell Host Microbe 2014; 16:412-418.
12. Asmal M, Luedemann C, Lavine CL, et al. Infection of monkeys by simianhuman immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. Virology 2014; 475C:37-45.
13. Humes D, Emery S, Laws E, Overbaugh J. A species-specific amino acid difference in the macaque CD4 receptor restricts replication by global circulating HIV-1 variants representing viruses from recent infection. J Virol 2012; 86:12472-12483.
14. Boyd DF, Peterson D, Haggarty BS, et al. Mutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer. J Virol 2015; 89:894-907.
15. Excler JL, Ake J, Robb ML, et al. Nonneutralizing functional antibodies: A new 'old' paradigm for HIV vaccines. Clin Vaccine Immunol 2014; 21:1023-1036.
16. Kramski M, Stratov I, Kent SJ. The role of HIV-specific antibody-dependent cellular cytotoxicity in HIV prevention and the influence of the HIV-1 Vpu protein. Aids 2015; 29:137-144.
17. Lewis GK, Guan Y, Kamin-Lewis R, et al. Epitope target structures of Fc-mediated effector function during HIV-1 acquisition. Curr Opin HIV AIDS 2014; 9:263-270.
18. Hessell AJ,Hangartner L,HunterM, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449:101-104.
19. Dugast AS, Chan Y, Hoffner M, et al. Lack of protection following passive transfer of polyclonal highly functional low-dose nonneutralizing antibodies. PLoS One 2014; 9:e97229.
20. Moog C, Dereuddre-Bosquet N, Teillaud JL, et al. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunol 2014; 7:46-56.
21. Ko SY, Pegu A, Rudicell RS, et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 2014; 514:642-645.
22. Pietzsch J, Gruell H, Bournazos S, et al. A mouse model for HIV-1 entry. Proc Natl Acad Sci USA 2012; 109:15859-15864.
23. Bournazos S, Klein F, Pietzsch J, et al. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 2014; 158: 1243-1253.
24. Burton DR, Hessell AJ, Keele BF, et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci USA 2011; 108:11181-11186.
25. Lux A, Nimmerjahn F. Of mice and men: The need for humanized mouse models to study human IgG activity in vivo. J Clin Immunol 2013; 33 (Suppl 1):S4-S8.
26. Smith P, DiLillo DJ, Bournazos S, et al. Mouse model recapitulating human Fcgamma receptor structural and functional diversity. Proc Natl Acad Sci USA 2012; 109:6181-6186.
27. Moldt B, Hessell AJ. FcgRs cross species. In: Nimmerjahn A and Ackerman M. Antibody Fc: linking adaptive and innate immunity. Philadelphia, PA: Elsevier 2013.
28. Demberg T, Mohanram V, Venzon D, Robert-Guroff M. Phenotypes and distribution of mucosal memory B-cell populations in the SIV/SHIV rhesus macaque model. Clin Immunol 2014; 153:264-276.
29. Thomas MA, Demberg T, Vargas-Inchaustegui DA, et al. Rhesus macaque rectal and duodenal tissues exhibit B-cell sub-populations distinct from peripheral blood that continuously secrete antigen-specific IgA in short-term explant cultures. Vaccine 2014; 32:872-880.
30. Barnett SW, Burke B, Sun Y, et al. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J Virol 2010; 84:5975-5985.
31. Bogers WM, Davis D, Baak I, et al. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology 2008; 382:217-225.
32. Ng CT, Jaworski JP, Jayaraman P, et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med 2010; 16:1117-1119.
33. Jaworski JP,Kobie J, Brower Z, et al. Neutralizing polyclonal IgGpresent during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques. J Virol 2013; 87:10447-10459.
34. Mascola JR, Lewis MG, Stiegler G, et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73:4009-4018.
35. Baba TW, Liska V, Hofmann-Lehmann R, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6:200-206.
36. Parren PW, Marx PA, Hessell AJ, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001; 75:8340-8347.
37. Hessell AJ, Poignard P, Hunter M, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009; 15:951-954.
38. Hessell AJ, Rakasz EG, Poignard P, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009; 5:e1000433.
39. Nishimura Y, Igarashi T, Haigwood N, et al. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol 2002; 76:2123-2130.
40. Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012; 337:183-186.
41. Kwong PD, Mascola JR. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012; 37:412-425.
42. Moldt B, Rakasz EG, Schultz N, et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci USA 2012; 109:18921-18925.
43. Shingai M, Donau OK, Plishka RJ, et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med 2014; 211:2061-2074.
44. Pegu A, Yang ZY, Boyington JC, et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med 2014; 6:243ra88.
45. Rudicell RS, Kwon YD, Ko SY, et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol 2014; 88:12669-12682.
46. Klein F, Halper-Stromberg A, Horwitz JA, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012; 492:118-122.
47. Barouch DH, Whitney JB, Moldt B, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013; 503:224-228.
48. Shingai M, Nishimura Y, Klein F, et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013; 503:277-280.
49. Halper-Stromberg A, Lu CL, Klein F, et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 2014; 158:989-999.
50. Balazs AB, Ouyang Y, Hong CM, et al. Vectored immunoprophylaxis protects humanized mice frommucosal HIV transmission. Nat Med 2014; 20:296-300.
51. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
52. Dobard C, Sharma S, Parikh UM, et al. Postexposure protection of macaques from vaginal SHIV infection by topical integrase inhibitors. Sci Transl Med 2014; 6:227ra35.
53. Klein F, Nogueira L, Nishimura Y, et al. Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. J Exp Med 2014; 211:2361-2372.
54. Hansen SG, Piatak M Jr, Ventura AB, et al. Immune clearance of highly pathogenic SIV infection. Nature 2013; 502:100-104.